Alvotech announced that the FDA has accepted its Biologics License Application for AVT16, an interchangeable biosimilar to Entyvio (vedolizumab), used to treat ulcerative colitis and Crohn’s disease. This acceptance marks a key step toward expanding patient access to biologic treatments in the U.S. AVT16 is developed and manufactured by Alvotech, with commercialization by Teva Pharmaceutical. If approved, AVT16 could be substituted for Entyvio at pharmacies without prescriber intervention, potentially lowering costs and increasing treatment options. The application is supported by comprehensive data demonstrating biosimilarity, and Alvotech is also developing AVT80, a related biosimilar for subcutaneous use.
Royal Unibrew initiated a share buy-back program in February 2026, which was increased from DKK 400 million to DKK 700 million in April 2026. The program is set to run until August 14, 2026, with total repurchases not exceeding DKK 700 million. As of...
Bavarian Nordic A/S has repurchased 50,169 of its own shares at an average price of DKK 182.35 since starting its share buyback program on June 2, 2026. The program allows the company to buy back shares up to a total value of DKK 150 million by July ...
Bavarian Nordic A/S has repurchased 50,169 shares at an average price of DKK 182.35, totaling DKK 9.15 million, as part of its share buy-back program running from June 2 to July 10, 2026. This program allows the company to buy back shares up to DKK 1...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of early June 2026, the bank has repurchased 1,160,124 shares at an average price of DKK 904.31, totaling about DKK...
Jyske Bank has continued its share repurchase program, acquiring shares valued at over DKK 1 billion since February 2026. The bank has bought a total of 1,160,124 treasury shares, representing 1.99% of its share capital, with transactions conducted u...
